NeoImmuneTech (A950220) Q1 2026 earnings summary

Executive summary

• Focused on T cell-based immunotherapies, with NT-I7 as the core pipeline and additional next-generation oncology assets in development.

• Business model includes licensing, partnerships, and government supply contracts, with a dual structure of R&D and commercial product sales.

• Exclusive North American rights to Endari®, an FDA-approved sickle cell disease therapy, with commercialization efforts underway.

Financial highlights

• Q1 2026 consolidated revenue: $359,672, primarily from research services and Endari-related service income.

• Operating loss for Q1 2026: $(4,245,868); net loss: $(5,150,192); basic and diluted EPS: $(0.16).

• Cash and cash equivalents at March 31, 2026: $23.2 million; total assets: $52.2 million; total equity: $35.9 million.

• R&D expenses for Q1 2026: $2.6 million, representing 726% of sales.

Outlook and guidance

• Anticipates revenue growth from Endari® sales following regulatory approvals and expanded commercialization.

• Expects future revenue from NT-I7 upon successful licensing or regulatory approval.